anxiolytic effects – mycolab.ai

Lysergic Acid Diethylamide (LSD) and the Heart: Exploring the Potential Impacts of LSD on Cardiovascular Function

mycolabadmin

This review examines how LSD affects the heart and blood vessels. While some evidence suggests LSD might protect against heart disease by reducing inflammation and blood clots, acute use can dangerously raise heart rate and blood pressure, and cause blood vessel constriction. Regular low-dose use raises concerns about potential valve damage. More research is needed to understand the full cardiovascular safety of LSD before it can be considered for medical use.

Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis

mycolabadmin

This comprehensive analysis of 10 clinical trials shows that psilocybin, a compound from magic mushrooms, can rapidly reduce depression symptoms starting within one day of administration and maintain these benefits for up to 6 months. Higher doses and two treatment sessions produced better results than single lower doses. While psilocybin did raise blood pressure temporarily, it was generally well-tolerated with dropout rates similar to placebo.

Psilocybin for clinical indications: A scoping review

mycolabadmin

This comprehensive review examined over 190 research studies on psilocybin (the active compound in magic mushrooms) as a medical treatment. The research shows promise for treating depression, anxiety, substance use disorders, and chronic pain, though most studies conducted so far have been small in size. While the evidence is encouraging, researchers emphasize the need for larger, better-designed clinical trials to fully understand psilocybin’s benefits and safety profile.

Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects

mycolabadmin

This study examined whether taking the antidepressant escitalopram before using psilocybin affects the drug’s effects. Twenty-three healthy participants took either escitalopram or placebo for two weeks, then received a dose of psilocybin. Surprisingly, escitalopram did not reduce the positive mood effects of psilocybin and actually reduced some negative side effects like anxiety and bad feelings. The combination appeared safe with no increased cardiovascular risks.

Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees

mycolabadmin

This study followed 52 people who attended psilocybin retreats in the Netherlands and measured their anxiety levels before, one day after, and one week after the experience. Participants showed significant reductions in both immediate anxiety (state anxiety) and long-term anxiety tendencies (trait anxiety) that lasted up to a week. The anxiety improvements were most strongly linked to feeling a sense of ego dissolution during the experience and to lasting changes in personality traits, particularly becoming less neurotic.

The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology

mycolabadmin

Researchers are rediscovering psychedelic compounds from traditional plants and fungi as potential treatments for mental health conditions and addiction. These substances work by interacting with brain chemistry, particularly serotonin systems, to reduce symptoms of depression, anxiety, and drug cravings. Recent clinical studies show promising results, especially for treating opioid addiction with single doses that can produce lasting improvements. However, more rigorous clinical trials are needed to fully understand how these compounds work and to establish safe, effective therapeutic protocols.

Down the rabbit hole – the psychological and neural mechanisms of psychedelic compounds and their use in treating mental health and medical conditions

mycolabadmin

Psychedelic compounds like psilocybin and LSD are showing significant promise for treating various mental health conditions including depression, anxiety, and PTSD. These substances appear to work through multiple mechanisms, including inducing profound mystical experiences and increasing neuroplasticity in the brain. Research indicates that environmental and contextual factors significantly influence how effective these treatments are, and even virtual reality experiences mimicking psychedelic effects show therapeutic benefits. The field is moving toward responsible, evidence-based clinical applications of psychedelics in psychiatry.

Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation

mycolabadmin

This study compared how well psilocybin therapy works for people with treatment-resistant depression depending on whether they were already off antidepressants or had stopped taking them for the study. The researchers found that both groups improved similarly in depression and anxiety symptoms after receiving psilocybin with therapy support. These results suggest that stopping antidepressants before psilocybin treatment may not reduce its effectiveness, though more research is needed to fully understand the relationship between medication status and treatment outcomes.

Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics

mycolabadmin

This review examines how psychedelic substances like psilocybin and LSD affect brain structure and function. Research shows these compounds can increase BDNF (a protein crucial for brain health) and promote the growth of new neurons and connections between brain cells. These biological changes may explain why psychedelics have shown promise in treating depression and anxiety, with effects lasting weeks after a single dose.

Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine

mycolabadmin

This review examines how psychedelic drugs like ketamine, MDMA, and psilocybin could offer new hope for people with PTSD by working on the brain differently than current medications. These compounds work quickly and help the brain form new neural connections that can help people process traumatic memories more effectively. When combined with therapy, these drugs show promise in reducing PTSD symptoms faster and more effectively than traditional antidepressants. The review also explains how doctors could use personalized medicine approaches using brain scans and genetic testing to determine which treatment would work best for each individual patient.

therapeutic action: anxiolytic effects